Clinical Trial Update: Safety, Pharmacokinetics,and Antiviral Activity of RV299 Against Respiratory Syncytical Virus (RSV) [Phase 1]

View source ↗

Summary

Phase 1 study evaluating safety, pharmacokinetics, and antiviral activity of RV299 against Respiratory Syncytial Virus. The trial is completed and results were …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• RV299

Snippet

Sponsor: Pfizer | Conditions: Respiratory Syncytial Virus (RSV) | Phase 1 | Status: COMPLETED | Results posted: 2024-10-21